

NICE technology appraisals for medicines

## Formulary adherence checklist

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

Technology appraisals 9  
CCG commissioned 1  
Non-CCG commissioned 6  
Not applicable 2  
CCG commissioned and approved 1(100%)  
Average days to compliance 63

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
<a href="#">Daratumumab monotherapy for treating relapsed and refractory multiple myeloma [TA783]</a>	Recommended	13/04/2022	TA	20/07/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
<a href="#">Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [TA784]</a>	Recommended	20/04/2022	TA	20/07/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
<a href="#">Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) [TA785]</a>	Not recommended	20/04/2022	TA					N/A	Link added to formulary
<a href="#">Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies [TA786]</a>	Recommended	27/04/2022	TA	27/07/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
<a href="#">Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable [TA787]</a>	Recommended	27/04/2022	TA	27/07/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
<a href="#">Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [TA788]</a>	Recommended	11/05/2022	TA	09/08/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
<a href="#">Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [TA789]</a>	Recommended	18/05/2022	TA	16/08/2022	Non-CCG			Tepotinib is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
<a href="#">TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) [TA790]</a>	Not recommended	25/05/2022	TA					N/A	Link added to formulary
<a href="#">Romosozumab for treating severe osteoporosis [TA791]</a>	Recommended	25/05/2022	TA	23/08/2022	CCG	27/07/2022	63	This technology is commissioned by integrated care systems and clinical commissioning groups.	To be brought to July APC